The scale and impact of mental illness across society is huge and new treatments are needed urgently. However, the lack of novel drug targets combined with the challenge of validating them pre-clinically, and the high failure rate in clinical trials have led to a reduced investment in drug discovery and development in the last decade and there have been no new effective types of treatment for over 30 years.
The Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies, working together to develop and deliver a portfolio of innovative and collaborative projects, which focus on identifying and validating novel drug targets for psychiatric diseases. Collectively, the strategic partners aim to provide approximately £4 million in research funding over three years, to deliver up to 10 high-value drug discovery projects.
The Consortium is managed by the Medicines Discovery Catapult and supported by Wellcome.
The Psychiatry Consortium is currently seeking project proposals which focus on the validation of novel molecular drug targets for mental health conditions. For successful applicants, in addition to project funding, we provide project management and delivery support and access to industry and commercialisation know-how.
This short talk will provide a brief introduction to the Psychiatry Consortium, details of opportunities for funding and information on how to apply.
